LongShort

I trade momentum stocks. Focus on Reversals. Use Trendlines, MACD and RSI. Know Fundamentals. My journal. Not Financial Advice.

[LongShort @vwap88]

$AAPL Cup and Handle.

[LongShort @vwap88]

$BRK.B

[LongShort @vwap88]

@TrumpDailyPosts Sleepy Joe likes filth! Inside and outside.

[LongShort @vwap88]

Minoxidil is an FDA-approved medication primarily used to treat hair loss (androgenetic alopecia) and stimulate hair growth. Initially developed as an oral pill for high blood pressure, it is now widely used in topical (liquid or foam) form applied directly to the scalp. [1, 2, 3, 4, 5, 6]

[LongShort @vwap88]

@laurahollis61 @fr_petros May the Wrath of God be upon the killers! Forgive but justice has to be done.

[LongShort @vwap88]

@TrumpDailyPosts Dumocrats

[LongShort @vwap88]

$GE Fundamentals behind the move up.

⁠GE Aerospace shares went up on June 5, 2026, closing at \(\$328.00\) ⁠General Electric Co ⁠General Electric Co, driven by a confluence of strong fundamental catalysts and optimistic defense and commercial sector contracts ⁠GE Aerospace Stock Price. [1, 2, 3]

Major growth drivers for General Electric Co include:

Strong First-Quarter Financials: Continued market enthusiasm from an earlier Q1 earnings beat ⁠General Electric Co Stock featuring 29% revenue growth, a massive 87% surge in orders, and a ($210) billion backlog GE Aerospace Stock Price.

Defense & Propulsion Wins: New propulsion systems were selected for U.S. Navy ocean surveillance vessels, high-voltage power systems qualified for military vehicles, and the successful completion of megawatt-class hybrid-electric engine testing funded by NASA GE Aerospace Stock Price.

Analyst Upgrades: Positive analyst ratings and upward price revisions (e.g., Deutsche Bank raised its target to \(\$380\) and Bernstein maintained a \(\$405\) target) further boosted institutional confidence GE Aerospace Stock Price. [1, 2]

[LongShort @vwap88]

$GE

[LongShort @vwap88]

$XLM Bullish action on 15min.

[LongShort @vwap88]

$UNH Fundamentals behind the move up.

UnitedHealth Group (⁠UNH) stock jumped over 5% on June 5, 2026, driven by a major ⁠Bank of America upgrade, raised Wall Street price targets across multiple firms, and an announced dividend increase ⁠Why Is UnitedHealth (UNH) Stock Rocketing Higher Today. [1, 2]

The specific catalysts that drove the stock higher included:

Bank of America Upgrade: Bank of America upgraded the stock to "Buy" from "Neutral" and raised its price target to $450 from $420 Why Is UnitedHealth (UNH) Stock Rocketing Higher Today. Analysts cited sustained moderation in medical costs and insurance usage, proving that strong first-quarter operational performance was structural and not just a temporary weather-related fluke Bank of America Just Upgraded UnitedHealth Stock. Here's Why.. [1, 2]

Morgan Stanley Target Hike: ⁠Morgan Stanley also raised its price target for ⁠UNH (to $453), reinforcing market confidence Why Is UnitedHealth Stock Gaining Thursday?. [1]

Dividend Increase: The company announced a 5% increase to its quarterly cash dividend to \(\$2.32\) per share, signaling management's confidence in their financial health and turnaround efforts Why Is UnitedHealth (UNH) Stock Rocketing Higher Today.

Broad Sector Rotation: Investors rotated out of more volatile, highly-valued technology stocks and into defensive blue-chip assets like ⁠UnitedHealth Stock Market News for Jun 5, 2026.

[LongShort @vwap88]

$UNH

[LongShort @vwap88]

$UNM Fundamentals behind the move up.

Unum Group (NYSE:UNM) stock climbed over 2% on June 5, 2026, reaching a new 52-week high of $86.84. The primary catalyst was a recent board-approved ~10% dividend increase, combined with strong Q1 earnings results, strong capital liquidity, and positive Wall Street analyst ratings. [1, 2, 3]

The stock's upward momentum was driven by several key factors:

Dividend Hike: The board announced a ~10% increase in the quarterly dividend to $0.505 per share, cementing a strong income-generating narrative. [1, 2]

Strong Q1 Results: Earlier in the quarter, the company reported Q1 EPS of \(\$2.14\) and revenue of \(\$3.36\) billion, outperforming Wall Street expectations. [1]

Institutional Support: The stock received an influx of positive sentiment and increased stakes from major institutional investors like Swedbank AB and Norges Bank. [1, 2]

[LongShort @vwap88]

$UNM

[LongShort @vwap88]

$JNJ Fundamentals behind the move up.

Johnson & Johnson (JNJ) stock jumped roughly 2% on June 5, 2026, driven by a favorable defense verdict in a major ovarian cancer talc powder trial in Los Angeles and positive analyst upgrades from firms like ⁠Guggenheim. The legal victory provided investors relief regarding the company's ongoing litigation risks. [1, 2, 3, 4]

Key Catalysts Behind the Stock Movement

Talcum Powder Trial Victory: On June 5, 2026, a Los Angeles Superior Court jury ruled in favor of J&J in a lawsuit brought by the families of three women. The jury found that ⁠Johnson & Johnson was not negligent in making and selling its talc-based cosmetic powders, alleviating concerns about massive potential liabilities. [1, 2, 3]

Analyst Upgrades: The legal win bolstered broader investor confidence, leading to a flurry of positive research notes and ratings updates from Wall Street firms, including a "Buy" rating from Guggenheim. [1, 2]

Robust Q1 2026 Earnings Momentum: The early June price action also reflected a delayed boost from the company's strong April performance, where J&J raised its full-year 2026 sales guidance and reported better-than-expected revenue and earnings per share. [1, 2, 3, 4]

Pipeline Successes: Investors had been encouraged by late-stage trial data released just days prior, showing that the company's experimental drug, nipocalimab, significantly reduced disease activity in a Phase 2 study for systemic lupus erythematosus. [1]

[LongShort @vwap88]

$JNJ Long

[LongShort @vwap88]

$LLY Fundamentals behind the move up.

LLY's stock rallied over 3% on June 5, 2026, reaching a new all-time high. The primary catalysts were an expansion of insurance coverage for its obesity drugs, positive pipeline and clinical trial data, and bullish analyst sentiment regarding its GLP-1 drug franchise. [1, 2, 3, 4]

Key Drivers of the Rally:

Expanded Insurance Coverage: CVS Caremark announced it would begin covering Lilly’s newly launched oral GLP-1 weight-loss pill, Foundayo (orforglipron), and would resume broader coverage for its injectable therapy, Zepbound. This critical PBM inclusion eliminates a major market-access gap, boosting patient affordability and market penetration. [1, 2, 3]

Strong Clinical Data: Strong data readouts for pipeline drugs—specifically positive Phase 3 clinical results for the investigational triple-agonist obesity drug retatrutide—stoked investor confidence. This added to enthusiasm from strong Q1 financial results and upgraded full-year 2026 guidance reported just weeks prior. [1, 3]

Bullish Wall Street: Major financial institutions reiterated strong "Overweight" ratings and raised global GLP-1 market forecasts (e.g., to \(\$150\) billion by 2030), with some analysts highlighting Lilly's dominant market share and positioning in the booming obesity space.

[LongShort @vwap88]

$LLY

[LongShort @vwap88]

$AAPL time to trim based on divergence of momentum and price action.

[LongShort @vwap88]

$AAPL Cup and Handle.

[LongShort @vwap88]

$CAH Fundamentals behind the move up.

Cardinal Health (⁠CAH) shares gained momentum in early June 2026, building on a robust earnings report ⁠from late April 2026. The underlying catalysts powering the stock higher included: [1, 2, 3]

Raised Fiscal 2026 Guidance: Cardinal Health repeatedly raised its full-year earnings forecast in 2026 to between US$10.15 and US$10.35 per share, driven by higher margins. [1]

Specialty Segment Growth: The ⁠Pharmaceutical and Specialty Solutions division (especially complex biologics, cancer treatments, and GLP-1 therapies) acted as a heavy driver for double-digit growth. [1, 2, 3]

[LongShort @vwap88]

$CAH Rotation to defensive stocks. Healthcare. LONG!

[LongShort @vwap88]

$GE

[LongShort @vwap88]

$XLMUSD Zoomed in. Always buy near 10EMA and trim when away from it. It's volatile. It's like 2 to 3 day swing trades.

[LongShort @vwap88]

$XLMUSD Seriously looking at XLM. Though there was like a pump and dump action, it could have an uptrend going forward from the multi-RSI readings.

[LongShort @vwap88]

$XLMUSD Seriously looking at XLM. Though there was like a pump and dump action, it could have an uptrend going forward from the multi-RSI readings.